Expanding Diagnosed and Drug-Treated Patient Populations Will Contribute to China’s Non-Small-Cell Lung Cancer Drug Market Growth

Expanding Diagnosed and Drug-Treated Patient Populations Will Contribute to China’s Non-Small-Cell Lung Cancer Drug Market Growth

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the number of diagnosed incident cases of non-small-cell lung cancer (NSCLC) in urban China will increase five percent annually between 2011 and 2016. This increase is due mainly to population aging in China and the continuous urbanization over the 2011-2016 study period. Additionally, according to the drug-treated patient population will expand from 2011 to 2016 as drug-treatment rates among NSCLC patients increase in both rural and urban regions. These factors will contribute to China’s NSCLC drug market growing from about $500 million in 2011 to more than $860 million in 2016.

The analysis also finds that changes in medical practice, specifically personalized medicine, will contribute to drug market growth as such an approach would optimize spending on premium-priced agents. A higher percentage of Chinese NSCLC patients harbor epidermal growth factor receptor (EGFR) mutations than Western patients, and this subgroup of patients reportedly has a better response to EGFR-tyrosine kinase inhibitors (TKIs), such as AstraZeneca’s Iressa and Roche’s Tarceva. Decision Resources anticipates more first-line use of EGFR-TKIs in patients with advanced NSCLC based on the personalized medicine approach between 2011 and 2016.

“Chinese oncologists we surveyed advocate increasing personalized treatment for NSCLC and desire targeted therapies such as Iressa and Tarceva,” said Decision Resources Analyst Jing Wu, M.S., M.B.A. “Physicians are excited by the opportunity to tailor regimens for NSCLC patients, and also expressed excitement about Pfizer’s emerging agent Xalkori which targets NSCLC patients who have gene translocations.”

The new report features extensive primary research with Chinese oncologists as well as a market outlook by drug and class through 2016 and non-small-cell lung cancer epidemiology through 2021.

Decision Resources is the first and only company to offer a syndicated report series for with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.